Leeward Financial Partners LLC Takes $244,000 Position in AbbVie Inc. $ABBV

Leeward Financial Partners LLC purchased a new stake in AbbVie Inc. (NYSE:ABBV) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,314 shares of the company’s stock, valued at approximately $244,000.

Several other large investors have also modified their holdings of the business. Haven Private LLC bought a new stake in shares of AbbVie in the 2nd quarter valued at about $219,000. Bridgewealth Advisory Group LLC bought a new stake in shares of AbbVie in the 2nd quarter valued at about $209,000. Cottage Street Advisors LLC raised its holdings in shares of AbbVie by 104.9% in the 2nd quarter. Cottage Street Advisors LLC now owns 9,168 shares of the company’s stock valued at $1,702,000 after purchasing an additional 4,693 shares in the last quarter. GAM Holding AG raised its holdings in shares of AbbVie by 14.4% in the 2nd quarter. GAM Holding AG now owns 7,802 shares of the company’s stock valued at $1,448,000 after purchasing an additional 981 shares in the last quarter. Finally, Linscomb Wealth Inc. raised its holdings in shares of AbbVie by 3.4% in the 2nd quarter. Linscomb Wealth Inc. now owns 90,165 shares of the company’s stock valued at $16,736,000 after purchasing an additional 2,928 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Wall Street Zen raised shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Citigroup reaffirmed a “neutral” rating on shares of AbbVie in a research report on Monday, October 13th. Guggenheim lifted their price objective on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Hsbc Global Res downgraded shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Finally, Daiwa America raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $234.80.

AbbVie Stock Down 4.4%

NYSE:ABBV opened at $218.14 on Friday. The company has a market cap of $385.35 billion, a PE ratio of 103.87, a P/E/G ratio of 1.42 and a beta of 0.51. AbbVie Inc. has a twelve month low of $163.81 and a twelve month high of $244.81. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The company’s 50 day moving average is $222.42 and its two-hundred day moving average is $200.77.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. AbbVie’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 312.38%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 13,295 shares of the company’s stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the sale, the executive vice president directly owned 58,247 shares of the company’s stock, valued at $11,562,611.97. This represents a 18.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the sale, the executive vice president directly owned 177,292 shares in the company, valued at $35,178,278.64. This trade represents a 19.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.25% of the stock is currently owned by insiders.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.